• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed < em > MGMT < /em > promoter methylated < em > IDH < /em > wildtype glioblastoma
CONCLUSIONS: The results from this multicentric trial indicate that-under real-life conditions-toxicity and survival estimates are comparable to the CeTeG/NOA-09 trial. TTFields therapy for at least eight weeks in combination with this regimen was independently associated with prolonged survival.PMID:36284931 | PMC:PMC9583686 | DOI:10.1093/noajnl/vdac137
Source: Adv Data - October 26, 2022 Category: Epidemiology Authors: Lazaros Lazaridis Elisabeth Bumes Dorothee C äcilia Spille Tim Schulz Sina Heider Sarina Agkatsev Teresa Schmidt Tobias Blau Christoph Oster Jonas Feldheim Walter Stummer Almuth Friederike Kessler Clemens Seidel Oliver Grauer Peter Hau Ulrich Sure Kathy Source Type: research

Temozolomide in grade III gastroenteropancreatic neuroendocrine neoplasms (G3 GEPNENs): A multicentre retrospective review
CONCLUSION: This is the largest TEM treatment series in G3 NEN, involving collaboration of several major North American NEN centers as a partnership. Thirty-six percent of patients showed some degree of radiographic response, and treatment was generally well-tolerated, although the median duration of response was short. Response rates and time to treatment failure were superior in the first-line setting. CAPTEM should be considered a viable treatment option in this setting. Further randomized trials are warranted.IMPLICATIONS FOR PRACTICE: Neuroendocrine neoplasms (NENs) are heterogeneous and optimal treatment for aggressi...
Source: The Oncologist - August 3, 2021 Category: Cancer & Oncology Authors: David L Chan Emily K Bergsland Jennifer A Chan Rujuta Gadgil Thorvardur R Halfdanarson Kathleen Hornbacker Virginia Kelly Pamela L Kunz Patrick W McGarrah Nitya P Raj Diane L Reidy Alia Thawer Julia Whitman Linda Wu Christoph Becker Simron Singh Source Type: research

Deciphering the glioblastoma phenotype by Computed Tomography radiomics
CONCLUSION: In this study clinical and CT radiomics features were used to predict OS in GBM. Discrimination between low-, middle- and high-risk patients based on the combined clinical and radiomics model was comparable to previous MRI-based models.PMID:33984349 | DOI:10.1016/j.radonc.2021.05.002
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - May 13, 2021 Category: Radiology Authors: Inge Compter Maikel Verduin Zhenwei Shi Henry C Woodruff Robert J Smeenk Tom Rozema Ralph T H Leijenaar Ren é Monshouwer Dani ëlle B P Eekers Ann Hoeben Alida A Postma Andre Dekker Dirk De Ruysscher Philippe Lambin Leonard Wee Source Type: research